Oliver Schnell

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp, Monika E. Hegi, Thierry Gorlia et al. · The Lancet Oncology · 2014 · 1K citations

Neuro-oncology, Glioma, Medicine +9

Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma

Vidhya M. Ravi, Paulina Will, Jan Kueckelhaus et al. · Cancer Cell · 2022 · 567 citations · Full text

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 556 citations · Full text

Hematological Malignancy, Neuro-oncology, Treatment Strategies +13

Mapping microglia states in the human brain through the integration of high-dimensional techniques

Roman Sankowski, Chotima Böttcher, Takahiro Masuda et al. · Nature Neuroscience · 2019 · 448 citations

Neuroimaging Biomarkers, High-dimensional Techniques, Cellular Neuroscience +14